← Back to Analyst Consensus 
RGNX Buy
REGENXBIO Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 11, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 5, 2026 | Mizuho | initiate | — → Outperform | — | 52% |
| Aug 25, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 25, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Aug 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 7, 2026 | Barclays | downgrade | Overweight → Equal-Weight | — | 53% |
| Jun 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 22, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Jun 22, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Jun 5, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 15, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| May 15, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Mar 9, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 6, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Feb 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $32 | 44% |
| Feb 10, 2026 | Goldman Sachs | maintain | Neutral → Neutral | $12 | 54% |
| Feb 10, 2026 | Morgan Stanley | maintain | Overweight → Overweight | $18 | 54% |
| Feb 10, 2026 | Chardan Capital | maintain | Buy → Buy | $50 | 46% |
| Jan 29, 2026 | Chardan Capital | maintain | Buy → Buy | $52 | 46% |
| Dec 19, 2025 | Stifel | maintain | Buy → Buy | $45 | 53% |
| Dec 15, 2025 | Leerink Partners | maintain | Outperform → Outperform | $20 | 51% |
| Nov 20, 2025 | Chardan Capital | maintain | Buy → Buy | $52 | 46% |
| Nov 7, 2025 | RBC Capital | maintain | Outperform → Outperform | $19 | 55% |
| Oct 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $34 | 44% |
| Sep 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $34 | 44% |
| Sep 8, 2025 | Chardan Capital | maintain | Buy → Buy | $52 | 46% |
| Aug 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $34 | 44% |
| Aug 8, 2025 | RBC Capital | maintain | Outperform → Outperform | $17 | 55% |
| Aug 8, 2025 | Barclays | maintain | Overweight → Overweight | $37 | 53% |
| Aug 8, 2025 | Chardan Capital | maintain | Buy → Buy | $52 | 46% |
| Jun 9, 2025 | Chardan Capital | maintain | Buy → Buy | $52 | 46% |
| Apr 17, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $12 | 54% |
| Mar 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $34 | 44% |
| Mar 20, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $34 | 44% |
| Mar 20, 2025 | Chardan Capital | maintain | Buy → Buy | $52 | 46% |
| Mar 17, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $34 | 44% |
| Mar 14, 2025 | Chardan Capital | maintain | Buy → Buy | $52 | 46% |
| Mar 14, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $24 | 54% |
| Feb 11, 2025 | Goldman Sachs | downgrade | Buy → Neutral | $14 | 54% |
| Jan 21, 2025 | RBC Capital | reiterate | Outperform → Outperform | $30 | 55% |
| Jan 15, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Dec 11, 2024 | RBC Capital | reiterate | Outperform → Outperform | $35 | 55% |
| Nov 21, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $36 | 44% |
| Nov 20, 2024 | Chardan Capital | maintain | Buy → Buy | $52 | 46% |
| Nov 7, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $40 | 44% |
| Oct 22, 2024 | Chardan Capital | maintain | Buy → Buy | $52 | 46% |
| Sep 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $39 | 44% |
| Aug 5, 2024 | Barclays | maintain | Overweight → Overweight | $50 | 53% |
| Aug 5, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $39 | 44% |
| Jun 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $38 | 44% |
| Jun 7, 2024 | Goldman Sachs | initiate | — → Buy | $38 | 54% |
Price Target Trend
Jun 20, 2026 Oct 27, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days